ZBNA
CRSP icon

Zions Bancorporation, National Association’s CRISPR Therapeutics CRSP Stock Holding History

Zions Bancorporation, National Association’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24K Hold
41
– – ﹤0.01% 1279
2026
Q1 		$1.95K Sell
41
-42
-51% -$2.21K ﹤0.01% 1221
2025
Q4 		$4.35K Buy
+83
New +$4.97K ﹤0.01% 906

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Zions Bancorporation, National Association's CRSP Position: Q2 2026 in Review

Zions Bancorporation, National Association held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 41 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

Zions Bancorporation, National Association first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.35K in Q4 2025. 167 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Zions Bancorporation, National Association held 41 shares of CRISPR Therapeutics worth $2.24K as of Q2 2026.
  • Zions Bancorporation, National Association left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1279 holding.
  • Zions Bancorporation, National Association first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Zions Bancorporation, National Association's CRISPR Therapeutics position peaked at $4.35K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.